Bambevi (bevacizumab)

pCPA File Number: 21474

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma

Sponsor/Manufacturer:

Apotex Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2021-06-11

Negotiation Process Concluded:

2021-08-18